Gilead Sciences Inc.

News & Events

Press Releases

In The Media

1. ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

   Business Wire MAY 23, 2025 8:30 AM EDT
   – Second Positive Phase 3 Trial in First-line Metastatic TNBC Where Trodelvy Has Demonstra...
   READ ARTICLE

2. Tomas Cihlar, Gilead Sciences, Named to TIME's List of 100 Most Influential People in the World for HIV Research

   ACCESS Newswire MAY 20, 2025 9:00 AM EDT
   NORTHAMPTON, MA / ACCESS Newswire / May 20, 2025 / Congratulations to our very own Tomas Cihl...
   READ ARTICLE

3. Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA

   Business Wire MAY 15, 2025 4:15 PM EDT
   – Late-Breaking Data from the Phase 3 ASCENT-04/KEYNOTE-D19 Study Evaluating Trodelvy &#...
   READ ARTICLE

4. Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories

   ACCESS Newswire MAY 15, 2025 9:25 AM EDT
   NORTHAMPTON, MA / ACCESS Newswire / May 15, 2025 / "Living with primary biliary cholangitis (P...
   READ ARTICLE

5. The 2024 Responsible Business and Impact Report Shares How Gilead Sciences Is Driving Change

   ACCESS Newswire MAY 13, 2025 8:50 AM EDT
   NORTHAMPTON, MA / ACCESS Newswire / May 13, 2025 / At Gilead, we innovate for impact. This com...
   READ ARTICLE

6. Earth Day Focus for Gilead Sciences - Every Action Has an Impact

   ACCESS Newswire MAY 8, 2025 9:00 AM EDT
   NORTHAMPTON, MA / ACCESS Newswire / May 8, 2025 / Creating a healthier world for all starts wi...
   READ ARTICLE

7. Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

   Business Wire MAY 7, 2025 2:30 AM EDT
   – 90% of Adults with Chronic Hepatitis Delta Virus (HDV) who Achieved Undetectable H...
   READ ARTICLE

8. Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

   Business Wire MAY 7, 2025 2:15 AM EDT
   – 60% of Participants with Prior Fibrate or Obeticholic Acid Treatment Achieve Biochemical...
   READ ARTICLE

9. Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"

   ACCESS Newswire MAY 6, 2025 8:40 AM EDT
   NORTHAMPTON, MA / ACCESS Newswire / May 6, 2025 / At Gilead, we set and achieve bold ambitions...
   READ ARTICLE

10. Gilead Sciences to Present at Upcoming Investor Conferences

    Business Wire APR 29, 2025 4:05 PM EDT
    Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the ...
    READ ARTICLE